Cho WC. Evidence-based anticancer materia medica. Hong Kong SAR: Springer; 2011. p. 390–406.
Book
Google Scholar
Huang K. Anesthetic and muscle-relaxing herbs: Chan Su. In: The pharmacology of Chinese herbs. 2nd edn. Boca Raton: CRC Press; 1999: 544.
Xu R, Xie HQ, Deng LL, Zhang JX, Yang FM, Liu JH, Hao XJ, Zhang YH. A new bufadienolide with cytotoxic activity from the Chinese traditional drug Ch’an Su. Chin J Nat Med. 2014;12(8):623–7.
CAS
PubMed
Google Scholar
Sakurai K, Yoshii E, Hashimoto H, Kubo K. Gas liquid chromatography of steroids of Ch’an Su. II. Reinvestigation on the determination of bufadienolides. Chem Pharm Bull. 1968;16(6):1140–3.
Article
CAS
Google Scholar
Shimizu Y, Morishita S. Metabolism and disposition of kyushin, a drug containing senso (ch’an su). Am J Chin Med. 1996;24(3–4):289–303.
CAS
PubMed
Google Scholar
Chang ZF, Jia DX, Bare J. Chinese materia medica. Beijing: Peoples Medical Publishing House; 2014.
Google Scholar
Su YH, Huang XQ, Zhang DZ, Zhang YN, Xie JM, Linh CQ. HPLC separation and determination of bufadienolide in cinobufacini injection. Chin Tradit Pat Med. 2003;25:24–7.
Google Scholar
Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP, Pan BR. Efficacy and safety of gemcitabine-oxaliplatin combined with Huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol. 2008;14(33):5210–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Xie X, Huang X, Li J, Lv X, Huang J, Tang S, Sun Y. Efficacy and safety of Huachansu combined with chemotherapy in advanced gastric cancer: a meta-analysis. Med Hypotheses. 2013;81(2):243–50.
Article
PubMed
Google Scholar
Yin JH, Zhu XY, Shi WD, Liu LM. Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft. BMC Complement Altern Med. 2014;14:483.
Article
PubMed
PubMed Central
Google Scholar
Zhou B, Wu F, Yuan L, Miao Z, Zhu S. Is huachansu beneficial in treating advanced non-small-cell lung cancer? Evidence from a meta-analysis of its efficacy combined with chemotherapy. Evid Based Complement Alternat Med. 2015;2015:408145.
PubMed
PubMed Central
Google Scholar
Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, et al. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 2009;115(22):5309–18.
Article
PubMed
Google Scholar
Wang L, Raju U, Milas L, Molkentine D, Zhang Z, Yang P, Cohen L, Meng Z, Liao Z. Huachansu, containing cardiac glycosides, enhances radiosensitivity of human lung cancer cells. Anticancer Res. 2011;31(6):2141–8.
CAS
PubMed
Google Scholar
Lee HJ, Koung FP, Kwon KR, Kang DI, Cohen L, Yang PY, Yoo HS. Comparative analysis of the bufonis venenum by using TLC, HPLC, and LC–MS for different extraction methods. J Pharmacopunct. 2012;15(4):52–65.
Article
Google Scholar
Dai LP, Wang ZM, Gao HM, Jiang X, Ding GZ. Determination of bufothionine in skin of Bufo bufo gargarizans and Huachansu injection. Zhongguo Zhong Yao Za Zhi. 2007;32(3):224–6.
CAS
PubMed
Google Scholar
Yang T, Shi R, Chang L, Tang K, Chen K, Yu G, Tian Y, Guo Y, He W, Song X, et al. Huachansu suppresses human bladder cancer cell growth through the Fas/Fasl and TNF-alpha/TNFR1 pathway in vitro and in vivo. J Exp Clin Cancer Res. 2015;34:21.
Article
PubMed
PubMed Central
CAS
Google Scholar
Toma S, Hirai Y, Sugimoto C, Shoji M, Oguni Y, Morishita S, Ito C, Horie M. Metabolic fate of bufalin and cinobufagin. Yakugaku Zasshi. 1991;111(11):687–94.
Article
CAS
PubMed
Google Scholar
Yang Z, Luo H, Wang H, Hou H. Preparative isolation of bufalin and cinobufagin from Chinese traditional medicine ChanSu. J Chromatogr Sci. 2008;46(1):81–5.
Article
CAS
PubMed
Google Scholar
Su YH, Nu X. Evaluation of pharmacodynamic effect of pharmaceutical agents of Chan Su. J Beijing Univ of TCM. 2001;24:51–4.
CAS
Google Scholar
Calderon-Montano JM, Burgos-Moron E, Orta ML, Maldonado-Navas D, Garcia-Dominguez I, Lopez-Lazaro M. Evaluating the cancer therapeutic potential of cardiac glycosides. Biomed Res Int. 2014;2014:794930.
Article
PubMed
PubMed Central
Google Scholar
Haux J. Digitoxin is a potential anticancer agent for several types of cancer. Med Hypotheses. 1999;53(6):543–8.
Article
CAS
PubMed
Google Scholar
Kamano Y, Nogawa T, Yamashita A, Hayashi M, Inoue M, Drasar P, Pettit GR. Isolation and structure of a 20,21-epoxybufenolide series from “Ch’an Su”. J Nat Prod. 2002;65(7):1001–5.
Article
CAS
PubMed
Google Scholar
Takai N, Kira N, Ishii T, Yoshida T, Nishida M, Nishida Y, Nasu K, Narahara H. Bufalin, a traditional oriental medicine, induces apoptosis in human cancer cells. Asian Pac J Cancer Prev. 2012;13(1):399–402.
Article
PubMed
Google Scholar
Datta P, Dasgupta A. Interactions between drugs and Asian medicine: displacement of digitoxin from protein binding site by bufalin, the constituent of Chinese medicines Chan Su and Lu-Shen-Wan. Ther Drug Monit. 2000;22(2):155–9.
Article
CAS
PubMed
Google Scholar
Dasgupta A, Emerson L. Neutralization of cardiac toxins oleandrin, oleandrigenin, bufalin, and cinobufotalin by digibind: monitoring the effect by measuring free digitoxin concentrations. Life Sci. 1998;63(9):781–8.
Article
CAS
PubMed
Google Scholar
Huang H, Zhang W. Bufalin induced apoptosis of bladder carcinoma cells through the inactivation of Na+K+-ATPase. Oncol Lett. 2018;16(3):3826–32.
PubMed
PubMed Central
Google Scholar
Li H, Wang P, Gao Y, Zhu X, Liu L, Cohen L, Meng Z, Yang P. Na+/K+-ATPase alpha3 mediates sensitivity of hepatocellular carcinoma cells to bufalin. Oncol Rep. 2011;25(3):825–30.
CAS
PubMed
Google Scholar
Nasu K, Nishida M, Ueda T, Takai N, Bing S, Narahara H, Miyakawa I. Bufalin induces apoptosis and the G0/G1 cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis. Mol Hum Reprod. 2005;11(11):817–23.
Article
CAS
PubMed
Google Scholar
Huang WW, Yang JS, Pai SJ, Wu PP, Chang SJ, Chueh FS, Fan MJ, Chiou SM, Kuo HM, Yeh CC, et al. Bufalin induces G0/G1 phase arrest through inhibiting the levels of cyclin D, cyclin E, CDK2 and CDK4, and triggers apoptosis via mitochondrial signaling pathway in T24 human bladder cancer cells. Mutat Res. 2012;732(1–2):26–33.
Article
CAS
PubMed
Google Scholar
Hsu CM, Tsai Y, Wan L, Tsai FJ. Bufalin induces G2/M phase arrest and triggers autophagy via the TNF, JNK, BECN-1 and ATG8 pathway in human hepatoma cells. Int J Oncol. 2013;43(1):338–48.
Article
CAS
PubMed
Google Scholar
Clifford RJ, Kaplan JH. Human breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells. PLoS ONE. 2013;8(12):e84306.
Article
PubMed
PubMed Central
CAS
Google Scholar
Laursen M, Gregersen JL, Yatime L, Nissen P, Fedosova NU. Structures and characterization of digoxin- and bufalin-bound Na+, K+-ATPase compared with the ouabain-bound complex. Proc Natl Acad Sci USA. 2015;112(6):1755–60.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lee S, Lee Y, Choi YJ, Han KS, Chung HW. Cyto-/genotoxic effects of the ethanol extract of Chan Su, a traditional Chinese medicine, in human cancer cell lines. J Ethnopharmacol. 2014;152(2):372–6.
Article
PubMed
Google Scholar
Okada M, Suga T, et al. Pharmacology of the principles isolated from Senso (Ch’an Su) the dried venom of the Chinese toad (IV). Asian Med J. 1960;3(4):155–60.
Google Scholar
Wang FZ, Gong H. Pharmacological study and clinical use of ChanSu. Forum Tradit Chin Med. 2003;18:50–2.
CAS
Google Scholar
Liu M, Feng LX, Sun P, Liu W, Wu WY, Jiang BH, Yang M, Hu LH, Guo DA, Liu X. A novel bufalin derivative exhibited stronger apoptosis-inducing effect than bufalin in A549 lung cancer cells and lower acute toxicity in mice. PLoS ONE. 2016;11(7):e0159789.
Article
PubMed
PubMed Central
CAS
Google Scholar
Chan WY, Ng TB, Yeung HW. Examination for toxicity of a Chinese drug, the toad glandular secretory product Chan su, in pregnant mice and embryos. Biol Neonate. 1995;67(5):376–80.
Article
CAS
PubMed
Google Scholar
Chen HT, Sun D, Peng YC, Kao PH, Wu YL. Novel augmentation by bufalin of protein kinase C-induced cyclooxygenase-2 and IL-8 production in human breast cancer cells. Innate Immun. 2017;23(1):54–66.
Article
CAS
PubMed
Google Scholar
Han KQ, Huang G, Gu W, Su YH, Huang XQ, Ling CQ. Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J Gastroenterol. 2007;13(24):3374–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen Y, Li M, Li Z, Gao P, Zhou X, Zhang J. Bufalin induces apoptosis in the U2OS human osteosarcoma cell line via triggering the mitochondrial pathway. Mol Med Rep. 2016;13(1):817–22.
Article
CAS
PubMed
Google Scholar
Ding DW, Zhang YH, Huang XE, An Q, Zhang X. Bufalin induces mitochondrial pathway-mediated apoptosis in lung adenocarcinoma cells. Asian Pac J Cancer Prev. 2014;15(23):10495–500.
Article
PubMed
Google Scholar
Efuet ET, Ding XP, Cartwright C, Pan Y, Cohen L, Yang P. Huachansu mediates cell death in non-Hodgkin’s lymphoma by induction of caspase-3 and inhibition of MAP kinase. Int J Oncol. 2015;47(2):592–600.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hong SH, Choi YH. Bufalin induces apoptosis through activation of both the intrinsic and extrinsic pathways in human bladder cancer cells. Oncol Rep. 2012;27(1):114–20.
CAS
PubMed
Google Scholar
Hsiao YP, Yu CS, Yu CC, Yang JS, Chiang JH, Lu CC, Huang HY, Tang NY, Yang JH, Huang AC, et al. Triggering apoptotic death of human malignant melanoma a375.s2 cells by bufalin: involvement of caspase cascade-dependent and independent mitochondrial signaling pathways. Evid Based Complement Alternat Med. 2012;2012:591241.
PubMed
PubMed Central
Google Scholar
Jiang L, Zhao MN, Liu TY, Wu XS, Weng H, Ding Q, Shu YJ, Bao RF, Li ML, Mu JS, et al. Bufalin induces cell cycle arrest and apoptosis in gallbladder carcinoma cells. Tumour Biol. 2014;35(11):10931–41.
Article
CAS
PubMed
Google Scholar
Jiang Y, Zhang Y, Luan J, Duan H, Zhang F, Yagasaki K, Zhang G. Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action. Cytotechnology. 2010;62(6):573–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li M, Yu X, Guo H, Sun L, Wang A, Liu Q, Wang X, Li J. Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells. Tumour Biol. 2014;35(3):2461–71.
Article
CAS
PubMed
Google Scholar
Masuda Y, Kawazoe N, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk Res. 1995;19(8):549–56.
Article
CAS
PubMed
Google Scholar
Miao Q, Bi LL, Li X, Miao S, Zhang J, Zhang S, Yang Q, Xie YH, Zhang J, Wang SW. Anticancer effects of bufalin on human hepatocellular carcinoma HepG2 cells: roles of apoptosis and autophagy. Int J Mol Sci. 2013;14(1):1370–82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sun L, Chen T, Wang X, Chen Y, Wei X. Bufalin induces reactive oxygen species dependent bax translocation and apoptosis in ASTC-a-1 cells. Evid Based Complement Alternat Med. 2011;2011:249090.
Article
PubMed
PubMed Central
Google Scholar
Wang D, Bi Z. Bufalin inhibited the growth of human osteosarcoma MG-63 cells via down-regulation of Bcl-2/Bax and triggering of the mitochondrial pathway. Tumour Biol. 2014;35(5):4885–90.
Article
CAS
PubMed
Google Scholar
Watabe M, Kawazoe N, Masuda Y, Nakajo S, Nakaya K. Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Cancer Res. 1997;57(15):3097–100.
CAS
PubMed
Google Scholar
Yin PH, Liu X, Qiu YY, Cai JF, Qin JM, Zhu HR, Li Q. Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: new hope for cancer patients. Asian Pac J Cancer Prev. 2012;13(11):5339–43.
Article
PubMed
Google Scholar
Arnaud-Batista FJ, Costa GT, Oliveira IM, Costa PP, Santos CF, Fonteles MC, Uchoa DE, Silveira ER, Cardi BA, Carvalho KM, et al. Natriuretic effect of bufalin in isolated rat kidneys involves activation of the Na+–K+-ATPase-Src kinase pathway. Am J Physiol Renal Physiol. 2012;302(8):F959–66.
Article
CAS
PubMed
Google Scholar
Song X, Zhang C, Zhao M, Chen H, Liu X, Chen J, Lonard DM, Qin L, Xu J, Wang X, et al. Steroid receptor coactivator-3 (SRC-3/AIB1) as a novel therapeutic target in triple negative breast cancer and its inhibition with a phospho-bufalin prodrug. PLoS ONE. 2015;10(10):e0140011.
Article
PubMed
PubMed Central
CAS
Google Scholar
Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill TG, Wang J, Qi R, Matzuk AJ, Song X, Madoux F, et al. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 2014;74(5):1506–17.
Article
CAS
PubMed
PubMed Central
Google Scholar
Calderon-Montano JM, Burgos-Moron E, Orta ML, Garcia-Dominguez I, Maldonado-Navas D, Lopez-Lazaro M. Bufalin is a steroid receptor coactivator inhibitor-letter. Cancer Res. 2015;75(6):1156.
Article
CAS
PubMed
Google Scholar
Lonard DM, Xu J, O’Malley BW. Bufalin is a steroid receptor coactivator inhibitor-response. Cancer Res. 2015;75(6):1157.
Article
CAS
PubMed
PubMed Central
Google Scholar
Xie CM, Chan WY, Yu S, Zhao J, Cheng CH. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med. 2011;51(7):1365–75.
Article
CAS
PubMed
Google Scholar
Gao Y, Li HX, Xu LT, Wang P, Xu LY, Cohen L, Yang PY, Gu K, Meng ZQ. Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. Mol Biol Rep. 2012;39(2):1683–9.
Article
CAS
PubMed
Google Scholar
Wang H, Zhang C, Chi H, Meng Z. Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins. Mol Med Rep. 2018;17(6):8101–10.
CAS
PubMed
PubMed Central
Google Scholar
Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang H, Zhang C, Chi H, Meng Z. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. Int J Oncol. 2018;52(6):2051–60.
CAS
PubMed
Google Scholar
Wang H, Zhang C, Ning Z, Xu L, Zhu X, Meng Z. Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling. Int J Oncol. 2016;48(3):1229–41.
Article
CAS
PubMed
Google Scholar
Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25(1):9–34.
Article
CAS
PubMed
Google Scholar
Gai JQ, Sheng X, Qin JM, Sun K, Zhao W, Ni L. The effect and mechanism of bufalin on regulating hepatocellular carcinoma cell invasion and metastasis via Wnt/beta-catenin signaling pathway. Int J Oncol. 2016;48(1):338–48.
Article
CAS
PubMed
Google Scholar
Sheng X, Sun X, Sun K, Sui H, Qin J, Li Q. Inhibitory effect of bufalin combined with Hedgehog signaling pathway inhibitors on proliferation and invasion and metastasis of liver cancer cells. Int J Oncol. 2016;49(4):1513–24.
Article
CAS
PubMed
Google Scholar
Chen YY, Lu HF, Hsu SC, Kuo CL, Chang SJ, Lin JJ, Wu PP, Liu JY, Lee CH, Chung JG, et al. Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK-Hep1 cells through the inhibitions of NF-kB and matrix metalloproteinase-2/-9-signaling pathways. Environ Toxicol. 2015;30(1):74–82.
Article
PubMed
CAS
Google Scholar
Chueh FS, Chen YY, Huang AC, Ho HC, Liao CL, Yang JS, Kuo CL, Chung JG. Bufalin-inhibited migration and invasion in human osteosarcoma U-2 OS cells is carried out by suppression of the matrix metalloproteinase-2, ERK, and JNK signaling pathways. Environ Toxicol. 2014;29(1):21–9.
Article
CAS
PubMed
Google Scholar
Wu SH, Hsiao YT, Kuo CL, Yu FS, Hsu SC, Wu PP, Chen JC, Hsia TC, Liu HC, Hsu WH, et al. Bufalin inhibits NCI-H460 human lung cancer cell metastasis in vitro by inhibiting MAPKs, MMPs, and NF-kappaB pathways. Am J Chin Med. 2015;43(6):1247–64.
Article
CAS
PubMed
Google Scholar
Qiu DZ, Zhang ZJ, Wu WZ, Yang YK. Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells. BMC Complement Altern Med. 2013;13:185.
Article
PubMed
PubMed Central
CAS
Google Scholar
Zhang ZJ, Yang YK, Wu WZ. Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice. J Transl Med. 2014;12:57.
Article
PubMed
PubMed Central
CAS
Google Scholar
Yu Z, Feng H, Sun X, Zhuo Y, Li M, Zhou Z, Huang L, Jiang Y, Zhu X, Zhang X, et al. Bufalin suppresses hepatocarcinogenesis by targeting beta-catenin/TCF signaling via cell cycle-related kinase. Sci Rep. 2018;8(1):3891.
Article
PubMed
PubMed Central
CAS
Google Scholar
Huang AC, Yang MD, Hsiao YT, Lin TS, Ma YS, Peng SF, Hsia TC, Cheng YD, Kuo CL, Chung JG. Bufalin inhibits gefitinib resistant NCI-H460 human lung cancer cell migration and invasion in vitro. J Ethnopharmacol. 2016;194:1043–50.
Article
CAS
PubMed
Google Scholar
Kang X, Lu P, Cui Y, Wang Y, Zhang Q, Gong Y, Xu Z. Bufalin reverses hepatocyte growth factor-induced resistance to afatinib in H1975 lung cancer cells. Zhonghua Zhong Liu Za Zhi. 2015;37(7):490–6.
PubMed
Google Scholar
Wang H, Zhang C, Xu L, Zang K, Ning Z, Jiang F, Chi H, Zhu X, Meng Z. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1alpha via the PI3K/AKT/mTOR pathway. Oncotarget. 2016;7(15):20193–208.
PubMed
PubMed Central
Google Scholar
Wang J, Cai H, Xia Y, Wang S, Xing L, Chen C, Zhang Y, Xu J, Yin P, Jiang Y, et al. Bufalin inhibits gastric cancer invasion and metastasis by down-regulating Wnt/ASCL2 expression. Oncotarget. 2018;9(34):23320–33.
PubMed
PubMed Central
Google Scholar
Wang J, Xia Y, Zuo Q, Chen T. Molecular mechanisms underlying the antimetastatic activity of bufalin. Mol Clin Oncol. 2018;8(5):631–6.
PubMed
PubMed Central
Google Scholar
Zhao L, Liu S, Che X, Hou K, Ma Y, Li C, Wen T, Fan Y, Hu X, Liu Y, et al. Bufalin inhibits TGF-beta-induced epithelial-to-mesenchymal transition and migration in human lung cancer A549 cells by downregulating TGF-beta receptors. Int J Mol Med. 2015;36(3):645–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu F, Tong D, Li H, Liu M, Li J, Wang Z, Cheng X. Bufalin enhances antitumor effect of paclitaxel on cervical tumorigenesis via inhibiting the integrin alpha2/beta5/FAK signaling pathway. Oncotarget. 2016;7(8):8896–907.
PubMed
PubMed Central
Google Scholar
Xie J, Lin W, Huang L, Xu N, Xu A, Chen B, Watanabe M, Liu C, Huang P. Bufalin suppresses the proliferation and metastasis of renal cell carcinoma by inhibiting the PI3K/Akt/mTOR signaling pathway. Oncol Lett. 2018;16(3):3867–73.
PubMed
PubMed Central
Google Scholar
Wang H, Ning Z, Li Y, Zhu X, Meng Z. Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via Hedgehog signaling. Mol Med Rep. 2016;14(3):1907–14.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ji D, Liang Z, Liu G, Zhao G, Fang J. Bufalin attenuates cancer-induced pain and bone destruction in a model of bone cancer. Naunyn Schmiedebergs Arch Pharmacol. 2017;390(12):1211–9.
Article
CAS
PubMed
Google Scholar
Ozdemir A, Simay YD, Ibisoglu B, Yaren B, Bulbul D, Ark M. Cardiac glycoside-induced cell death and Rho/Rho kinase pathway: implication of different regulation in cancer cell lines. Steroids. 2016;109:29–43.
Article
CAS
PubMed
Google Scholar
Li H, Hu S, Pang Y, Li M, Chen L, Liu F, Liu M, Wang Z, Cheng X. Bufalin inhibits glycolysis-induced cell growth and proliferation through the suppression of Integrin beta2/FAK signaling pathway in ovarian cancer. Am J Cancer Res. 2018;8(7):1288–96.
PubMed
PubMed Central
Google Scholar
Xie XB, Yin JQ, Wen LL, Gao ZH, Zou CY, Wang J, Huang G, Tang QL, Colombo C, He WL, et al. Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research. PLoS ONE. 2012;7(10):e47375.
Article
CAS
PubMed
PubMed Central
Google Scholar
Xie XB, Wen LL, Yin JQ, Liao HY, Zou CY, Wang B, Huang G, Shen JN. Proteomics research of bufalin-induced apoptosis in osteosarcoma cell lines. Zhongguo Zhong Yao Za Zhi. 2014;39(14):2739–43.
CAS
PubMed
Google Scholar
Zhang DM, Feng LX, Liu M, Jin WH, Luo J, Nie AY, Zhou Y, Li Y, Wu WY, Jiang BH, et al. Possible target-related proteins and signal network of bufalin in A549 cells suggested by both iTRAQ-based and label-free proteomic analysis. Proteomics. 2016;16(6):935–45.
Article
CAS
PubMed
Google Scholar
Wu SH, Hsiao YT, Chen JC, Lin JH, Hsu SC, Hsia TC, Yang ST, Hsu WH, Chung JG. Bufalin alters gene expressions associated DNA damage, cell cycle, and apoptosis in human lung cancer NCI-H460 cells in vitro. Molecules. 2014;19(5):6047–57.
Article
PubMed
PubMed Central
CAS
Google Scholar
Fell DA. Beyond genomics. Trends Genet. 2001;17(12):680–2.
Article
CAS
PubMed
Google Scholar
Wu XY, Tian F, Su MH, Wu M, Huang Y, Hu LH, Jin L, Zhu XJ. BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway. Int Immunopharmacol. 2018;64:24–32.
Article
CAS
PubMed
Google Scholar
Sun P, Feng LX, Zhang DM, Liu M, Liu W, Mi T, Wu WY, Jiang BH, Yang M, Hu LH, et al. Bufalin derivative BF211 inhibits proteasome activity in human lung cancer cells in vitro by inhibiting beta1 subunit expression and disrupting proteasome assembly. Acta Pharmacol Sin. 2016;37(7):908–18.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hu Q, Liang B, Sun Y, Guo XL, Bao YJ, Xie DH, Zhou M, Duan YR, Yin PH, Peng ZH. Preparation of bufalin-loaded pluronic polyetherimide nanoparticles, cellular uptake, distribution, and effect on colorectal cancer. Int J Nanomed. 2014;9:4035–41.
Google Scholar
Yang Z, Liu J, Huang Q, Zhang Z, Zhang J, Pan Y, Yang Y, Cheng D. Radiosynthesis and pharmacokinetics of [(18)F]fluoroethyl bufalin in hepatocellular carcinoma-bearing mice. Onco Targets Ther. 2017;10:329–38.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zou A, Zhao X, Handge UA, Garamus VM, Willumeit-Romer R, Yin P. Folate receptor targeted bufalin/beta-cyclodextrin supramolecular inclusion complex for enhanced solubility and anti-tumor efficiency of bufalin. Mater Sci Eng C Mater Biol Appl. 2017;78:609–18.
Article
CAS
PubMed
Google Scholar
Chen Q, Liu J. Transferrin and folic acid co-modified bufalin-loaded nanoliposomes: preparation, characterization, and application in anticancer activity. Int J Nanomed. 2018;13:6009–18.
Article
Google Scholar
Yuan J, Zhou X, Cao W, Bi L, Zhang Y, Yang Q, Wang S. Improved antitumor efficacy and pharmacokinetics of bufalin via PEGylated liposomes. Nanoscale Res Lett. 2017;12(1):585.
Article
PubMed
PubMed Central
CAS
Google Scholar
Li Y, Yuan J, Yang Q, Cao W, Zhou X, Xie Y, Tu H, Zhang Y, Wang S. Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma. Int J Nanomed. 2014;9:5683–700.
Google Scholar
Shi XJ, Qiu YY, Yu H, Liu C, Yuan YX, Yin PH, Liu T. Increasing the anticancer performance of bufalin (BUF) by introducing an endosome-escaping polymer and tumor-targeting peptide in the design of a polymeric prodrug. Colloids Surf B Biointerfaces. 2018;166:224–34.
Article
CAS
PubMed
Google Scholar
Liu T, Jia T, Yuan X, Liu C, Sun J, Ni Z, Xu J, Wang X, Yuan Y. Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo. Int J Nanomed. 2016;11:2235–50.
Article
CAS
Google Scholar
Liu T, Yuan X, Jia T, Liu C, Ni Z, Qin Z, Yuan Y. Polymeric prodrug of bufalin for increasing solubility and stability: synthesis and anticancer study in vitro and in vivo. Int J Pharm. 2016;506(1–2):382–93.
Article
CAS
PubMed
Google Scholar
Zhang H, Huang N, Yang G, Lin Q, Su Y. Bufalin-loaded bovine serum albumin nanoparticles demonstrated improved anti-tumor activity against hepatocellular carcinoma: preparation, characterization, pharmacokinetics and tissue distribution. Oncotarget. 2017;8(38):63311–23.
PubMed
PubMed Central
Google Scholar
Liu Y, Wang P, Sun C, Zhao J, Du Y, Shi F, Feng N. Bioadhesion and enhanced bioavailability by wheat germ agglutinin-grafted lipid nanoparticles for oral delivery of poorly water-soluble drug bufalin. Int J Pharm. 2011;419(1–2):260–5.
Article
CAS
PubMed
Google Scholar
Tian X, Yin H, Zhang S, Luo Y, Xu K, Ma P, Sui C, Meng F, Liu Y, Jiang Y, et al. Bufalin loaded biotinylated chitosan nanoparticles: an efficient drug delivery system for targeted chemotherapy against breast carcinoma. Eur J Pharm Biopharm. 2014;87(3):445–53.
Article
CAS
PubMed
Google Scholar
Yin P, Wang Y, Qiu Y, Hou L, Liu X, Qin J, Duan Y, Liu P, Qiu M, Li Q. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. Int J Nanomed. 2012;7:3961–9.
CAS
Google Scholar
Zhang HQ, Yin ZF, Sheng JY, Jiang ZQ, Wu BY, Su YH. A comparison study of pharmacokinetics between bufalin-loaded bovine serum albumin nanoparticles and bufalin in rats. Zhong Xi Yi Jie He Xue Bao. 2012;10(6):674–80.
Article
CAS
PubMed
Google Scholar
Bick RJ, Poindexter BJ, Sweney RR, Dasgupta A. Effects of Chan Su, a traditional Chinese medicine, on the calcium transients of isolated cardiomyocytes: cardiotoxicity due to more than Na, K-ATPase blocking. Life Sci. 2002;72(6):699–709.
Article
CAS
PubMed
Google Scholar
Koh CH, Wu J, Chung YY, Liu Z, Zhang RR, Chong K, Korzh V, Ting S, Oh S, Shim W, et al. Electronic supplementary material Identification of a Na(+)/K(+)-ATPase inhibition-independent proarrhythmic ionic mechanisms of cardiac glycosides. Sci Rep. 2017;7(1):2465.
Article
PubMed
PubMed Central
CAS
Google Scholar
Nesher M, Shpolansky U, Viola N, Dvela M, Buzaglo N, Cohen Ben-Ami H, Rosen H, Lichtstein D. Ouabain attenuates cardiotoxicity induced by other cardiac steroids. Br J Pharmacol. 2010;160(2):346–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhao M, Liu Y, Jin B, Hou K. Inhibition effect of ethanol extract of Chinese toad venom on H22 ascites and solid tumors and its toxicity in mice. J Qilu Oncol. 2005;22:1705–9.
Google Scholar
Zhao M, Liu Y, Hou K, Zhu Z, Tian X. Inhibition effect of ethanol extract of toad venom on S180 ascites and solid tumors and its toxicity in mice. Shanxi Med J. 2006;03:189–92.
Google Scholar
Zhao M, Liu Y, Hou K. Inhibition effect of ethanol extract of toad venom on Ehrlich’s ascites carcinomas and its toxicity in mice. Shanxi Med J. 2006;06:479–82.
Google Scholar
Zhu LB, Liu QY. Clinical observation of cinobufacin combined with cisplatin through intrapericardial infusion in treatment of malignant pericardial effusion. Chin J Med Guide. 2009;09:1525–6.
Google Scholar
Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo N, Li XK, Tang W. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 2010;4(6):297–307.
PubMed
Google Scholar
Wang Z, Qi F, Cui Y, Zhao L, Sun X, Tang W, Cai P. An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics. Biosci Trends. 2018;12(3):220–39.
Article
PubMed
Google Scholar
Lin Y, Wang Z, Wang Z, Gan P. Clinical observation on cinobufotalin tablets combined with XELOX regimen in chemotherapy after colorectal cancer surgery. Chin Med Mod Distance Educ China. 2017;22:107–9.
Google Scholar
Meng Z, Liu F, Shen Y, Yang P, Cohen L, Huo Y, Zhao Q, Ng CS, Chang DZ, Garrett CR. A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC). J Clin Oncol. 2011;29:4127.
Article
Google Scholar
Zhakeer Z, Hadeer M, Tuerxun Z, Tuerxun K. Bufalin inhibits the inflammatory effects in asthmatic mice through the suppression of nuclear factor-kappa B activity. Pharmacology. 2017;99(3–4):179–87.
Article
CAS
PubMed
Google Scholar
Chang YW, Zhao YF, Cao YL, Gu W, Pang J, Zhan HS. Bufalin exerts inhibitory effects on IL-1beta-mediated proliferation and induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes. Inflammation. 2014;37(5):1552–9.
Article
CAS
PubMed
Google Scholar
Rong X, Ni W, Liu Y, Wen J, Qian C, Sun L, Wang J. Bufalin, a bioactive component of the Chinese medicine chansu, inhibits inflammation and invasion of human rheumatoid arthritis fibroblast-like synoviocytes. Inflammation. 2014;37(4):1050–8.
Article
CAS
PubMed
Google Scholar
Xie S, Spelmink L, Codemo M, Subramanian K, Putsep K, Henriques-Normark B, Olliver M. Cinobufagin modulates human innate immune responses and triggers antibacterial activity. PLoS ONE. 2016;11(8):e0160734.
Article
PubMed
PubMed Central
CAS
Google Scholar
Wen L, Huang Y, Xie X, Huang W, Yin J, Lin W, Jia Q, Zeng W. Anti-inflammatory and antinociceptive activities of bufalin in rodents. Mediat Inflamm. 2014;2014:171839.
Article
CAS
Google Scholar
Tongkao-On W, Gordon-Thomson C, Dixon KM, Song EJ, Luu T, Carter SE, Sequeira VB, Reeve VE, Mason RS. Novel vitamin D compounds and skin cancer prevention. Dermatoendocrinol. 2013;5(1):20–33.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lan YL, Wang X, Lou JC, Xing JS, Yu ZL, Wang H, Zou S, Ma X, Zhang B. Bufalin inhibits glioblastoma growth by promoting proteasomal degradation of the Na(+)/K(+)-ATPase alpha1 subunit. Biomed Pharmacother. 2018;103:204–15.
Article
CAS
PubMed
Google Scholar
Yan S, Qu X, Xu C, Zhu Z, Zhang L, Xu L, Song N, Teng Y, Liu Y. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells. J Cancer Res Clin Oncol. 2012;138(8):1279–89.
Article
CAS
PubMed
Google Scholar
Wang Q, Li C, Zhu Z, Teng Y, Che X, Wang Y, Ma Y, Wang Y, Zheng H, Liu Y, et al. miR-155-5p antagonizes the apoptotic effect of bufalin in triple-negative breast cancer cells. Anticancer Drugs. 2016;27(1):9–16.
Article
CAS
PubMed
Google Scholar
Pan S, Wang Y, Feng L, Fan C, Guo D, Liu X, Fan J. Study on proteomics of Hela cell apoptosis in bufalin-induced human cervical carcinoma. Zhongguo Zhong Yao Za Zhi. 2012;37(13):1998–2004.
PubMed
Google Scholar
Zhu Z, Li E, Liu Y, Gao Y, Sun H, Ma G, Wang Z, Liu X, Wang Q, Qu X, et al. Inhibition of Jak-STAT3 pathway enhances bufalin-induced apoptosis in colon cancer SW620 cells. World J Surg Oncol. 2012;10:228.
Article
PubMed
PubMed Central
Google Scholar
Zhang N, Xie Y, Tai Y, Gao Y, Guo W, Yu W, Li J, Feng X, Hao J, Gao Y, et al. Bufalin inhibits hTERT expression and colorectal cancer cell growth by targeting CPSF4. Cell Physiol Biochem. 2016;40(6):1559–69.
Article
CAS
PubMed
Google Scholar
Qiu YY, Hu Q, Tang QF, Feng W, Hu SJ, Liang B, Peng W, Yin PH. MicroRNA-497 and bufalin act synergistically to inhibit colorectal cancer metastasis. Tumour Biol. 2014;35(3):2599–606.
Article
CAS
PubMed
Google Scholar
Wang J, Chen C, Wang S, Zhang Y, Yin P, Gao Z, Xu J, Feng D, Zuo Q, Zhao R, et al. Bufalin inhibits HCT116 colon cancer cells and its orthotopic xenograft tumor in mice model through genes related to apoptotic and PTEN/AKT pathways. Gastroenterol Res Pract. 2015;2015:457193.
PubMed
PubMed Central
Google Scholar
Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med. 2008;21(5):637–43.
CAS
PubMed
Google Scholar
Lv J, Lin S, Peng P, Cai C, Deng J, Wang M, Li X, Lin R, Lin Y, Fang A, et al. Arenobufagin activates p53 to trigger esophageal squamous cell carcinoma cell apoptosis in vitro and in vivo. Onco Targets Ther. 2017;10:1261–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li A, Qu X, Li Z, Qu J, Song N, Ma Y, Liu Y. Secreted protein acidic and rich in cysteine antagonizes bufalin-induced apoptosis in gastric cancer cells. Mol Med Rep. 2015;12(2):2926–32.
Article
CAS
PubMed
Google Scholar
Tsai SC, Yang JS, Peng SF, Lu CC, Chiang JH, Chung JG, Lin MW, Lin JK, Amagaya S, Wai-Shan Chung C, et al. Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell death in SK-HEP-1 human hepatocellular carcinoma cells. Int J Oncol. 2012;41(4):1431–42.
Article
CAS
PubMed
Google Scholar
Zhai X, Lu J, Wang Y, Fang F, Li B, Gu W. Reversal effect of bufalin on multidrug resistance in K562/VCR vincristine-resistant leukemia cell line. J Tradit Chin Med. 2014;34(6):678–83.
Article
PubMed
Google Scholar
Wang LP, Zhao YN, Sun X, Gao RL. Effects of bufalin on up-regulating methylation of Wilm’s tumor 1 gene in human erythroid leukemic cells. Chin J Integr Med. 2017;23(4):288–94.
Article
CAS
PubMed
Google Scholar
Zhu Z, Sun H, Ma G, Wang Z, Li E, Liu Y, Liu Y. Bufalin induces lung cancer cell apoptosis via the inhibition of PI3K/Akt pathway. Int J Mol Sci. 2012;13(2):2025–35.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tsai SC, Lu CC, Lee CY, Lin YC, Chung JG, Kuo SC, Amagaya S, Chen FN, Chen MY, Chan SF, et al. AKT serine/threonine protein kinase modulates bufalin-triggered intrinsic pathway of apoptosis in CAL 27 human oral cancer cells. Int J Oncol. 2012;41(5):1683–92.
Article
CAS
PubMed
Google Scholar
Tian X, Dai S, Sun J, Jiang S, Sui C, Meng F, Li Y, Fu L, Jiang T, Wang Y, et al. Bufalin induces mitochondria-dependent apoptosis in pancreatic and oral cancer cells by downregulating hTERT expression via activation of the JNK/p38 pathway. Evid Based Complement Alternat Med. 2015;2015:546210.
PubMed
PubMed Central
Google Scholar
Zhang J, Sha J, Zhou Y, Han K, Wang Y, Su Y, Yin X, Hu H, Yao Y. Bufalin inhibits proliferation and induces apoptosis in osteosarcoma cells by downregulating MicroRNA-221. Evid Based Complement Alternat Med. 2016;2016:7319464.
PubMed
PubMed Central
Google Scholar
Yin JQ, Shen JN, Su WW, Wang J, Huang G, Jin S, Guo QC, Zou CY, Li HM, Li FB. Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant cell lines. Acta Pharmacol Sin. 2007;28(5):712–20.
Article
CAS
PubMed
Google Scholar
Chou HY, Chueh FS, Ma YS, Wu RS, Liao CL, Chu YL, Fan MJ, Huang WW, Chung JG. Bufalin induced apoptosis in SCC4 human tongue cancer cells by decreasing Bcl2 and increasing Bax expression via the mitochondria dependent pathway. Mol Med Rep. 2017;16(6):7959–66.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yuan B, He J, Kisoh K, Hayashi H, Tanaka S, Si N, Zhao HY, Hirano T, Bian B, Takagi N. Effects of active bufadienolide compounds on human cancer cells and CD4+ CD25+ Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells. Oncol Rep. 2016;36(3):1377–84.
Article
CAS
PubMed
Google Scholar
Yuan ZT, Shi XJ, Yuan YX, Qiu YY, Zou Y, Liu C, Yu H, He X, Xu K, Yin PH. Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer. Oncotarget. 2017;8(29):48012–26.
Article
PubMed
PubMed Central
Google Scholar
Sun J, Xu K, Qiu Y, Gao H, Xu J, Tang Q, Yin P. Bufalin reverses acquired drug resistance by inhibiting stemness in colorectal cancer cells. Oncol Rep. 2017;38(3):1420–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Xiang RF, Wang Y, Zhang N, Xu WB, Cao Y, Tong J, Li JM, Wu YL, Yan H. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death Dis. 2017;8(5):e2776.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen Y, Guo Q, Zhang B, Kang M, Xie Q, Wu Y. Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer. Oncol Lett. 2012;4(4):792–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu X, Xiao XY, Shou QY, Yan JF, Chen L, Fu HY, Wang JC. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-kappaB pathway. J Ethnopharmacol. 2016;193:538–45.
Article
CAS
PubMed
Google Scholar
Wu SH, Bau DT, Hsiao YT, Lu KW, Hsia TC, Lien JC, Ko YC, Hsu WH, Yang ST, Huang YP, et al. Bufalin induces apoptosis in vitro and has antitumor activity against human lung cancer xenografts in vivo. Environ Toxicol. 2017;32(4):1305–17.
Article
CAS
PubMed
Google Scholar
Hong SH, Kim GY, Chang YC, Moon SK, Kim WJ, Choi YH. Bufalin prevents the migration and invasion of T24 bladder carcinoma cells through the inactivation of matrix metalloproteinases and modulation of tight junctions. Int J Oncol. 2013;42(1):277–86.
Article
CAS
PubMed
Google Scholar
Kang KH, Han MH, Jeong JW, Park C, Lee SH, Lee HW, Hong SH, Choi YH, Hong SH. Bufalin sensitizes human bladder carcinoma cells to TRAIL-mediated apoptosis. Oncol Lett. 2017;14(1):853–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dong Y, Yin S, Li J, Jiang C, Ye M, Hu H. Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway. Apoptosis. 2011;16(4):394–403.
Article
CAS
PubMed
Google Scholar
Yan S, Qu X, Xu L, Che X, Ma Y, Zhang L, Teng Y, Zou H, Liu Y. Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells. Anticancer Drugs. 2014;25(6):683–9.
CAS
PubMed
Google Scholar
Zou Z, Luo X, Nie P, Wu B, Zhang T, Wei Y, Wang W, Geng G, Jiang J, Mi Y. Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors. Biochem Biophys Res Commun. 2016;478(1):227–33.
Article
CAS
PubMed
Google Scholar
Xie CM, Liu XY, Yu S, Cheng CH. Cardiac glycosides block cancer growth through HIF-1alpha- and NF-kappaB-mediated Plk1. Carcinogenesis. 2013;34(8):1870–80.
Article
CAS
PubMed
Google Scholar
Zhao H, Zhao D, Tan G, Liu Y, Zhuang L, Liu T. Bufalin promotes apoptosis of gastric cancer by down-regulation of miR-298 targeting bax. Int J Clin Exp Med. 2015;8(3):3420–8.
CAS
PubMed
PubMed Central
Google Scholar
Zhao H, Zhao D, Jin H, Li H, Yang X, Zhuang L, Liu T. Bufalin reverses intrinsic and acquired drug resistance to cisplatin through the AKT signaling pathway in gastric cancer cells. Mol Med Rep. 2016;14(2):1817–22.
Article
CAS
PubMed
Google Scholar
Zhao H, Li Q, Pang J, Jin H, Li H, Yang X. Blocking autophagy enhances the pro-apoptotic effect of bufalin on human gastric cancer cells through endoplasmic reticulum stress. Biol Open. 2017;6(10):1416–22.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shen S, Zhang Y, Wang Z, Liu R, Gong X. Bufalin induces the interplay between apoptosis and autophagy in glioma cells through endoplasmic reticulum stress. Int J Biol Sci. 2014;10(2):212–24.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu T, Wu C, Weng G, Zhao Z, He X, Fu C, Sui Z, Huang SX. Bufalin inhibits cellular proliferation and cancer stem cell-like phenotypes via upregulation of MiR-203 in glioma. Cell Physiol Biochem. 2017;44(2):671–81.
Article
PubMed
Google Scholar
Qi F, Inagaki Y, Gao B, Cui X, Xu H, Kokudo N, Li A, Tang W. Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer Sci. 2011;102(5):951–8.
Article
CAS
PubMed
Google Scholar
Hu F, Han J, Zhai B, Ming X, Zhuang L, Liu Y, Pan S, Liu T. Blocking autophagy enhances the apoptosis effect of bufalin on human hepatocellular carcinoma cells through endoplasmic reticulum stress and JNK activation. Apoptosis. 2014;19(1):210–23.
Article
CAS
PubMed
Google Scholar
Gu W, Liu L, Fang FF, Huang F, Cheng BB, Li B. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells. Oncol Rep. 2014;31(1):216–22.
Article
CAS
PubMed
Google Scholar
Zhai B, Hu F, Yan H, Zhao D, Jin X, Fang T, Pan S, Sun X, Xu L. Bufalin reverses resistance to sorafenib by inhibiting Akt activation in hepatocellular carcinoma: the role of endoplasmic reticulum stress. PLoS ONE. 2015;10(9):e0138485.
Article
PubMed
PubMed Central
CAS
Google Scholar
Liu M, Feng LX, Sun P, Liu W, Mi T, Lei M, Wu W, Jiang B, Yang M, Hu L, et al. Knockdown of apolipoprotein E enhanced sensitivity of Hep3B cells to cardiac steroids via regulating Na+/K+-ATPase signalosome. Mol Cancer Ther. 2016;15(12):2955–65.
Article
CAS
PubMed
Google Scholar
Xia J, Inagaki Y, Gao J, Qi F, Song P, Han G, Sawakami T, Gao B, Luo C, Kokudo N, et al. Combination of cinobufacini and doxorubicin increases apoptosis of hepatocellular carcinoma cells through the Fas- and mitochondria-mediated pathways. Am J Chin Med. 2017;45(7):1537–56.
Article
CAS
PubMed
Google Scholar
Amano Y, Cho Y, Matsunawa M, Komiyama K, Makishima M. Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. J Steroid Biochem Mol Biol. 2009;114(3–5):144–51.
Article
CAS
PubMed
Google Scholar
Zhu Z, Li E, Liu Y, Gao Y, Sun H, Wang Y, Wang Z, Liu X, Wang Q, Liu Y. Bufalin induces the apoptosis of acute promyelocytic leukemia cells via the downregulation of survivin expression. Acta Haematol. 2012;128(3):144–50.
Article
CAS
PubMed
Google Scholar
Kang XH, Xu ZY, Gong YB, Wang LF, Wang ZQ, Xu L, Cao F, Liao MJ. Bufalin reverses HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via blockage of Met/PI3k/Akt pathway and induction of apoptosis. Evid Based Complement Alternat Med. 2013;2013:243859.
PubMed
PubMed Central
Google Scholar
Kang XH, Zhang JH, Zhang QQ, Cui YH, Wang Y, Kou WZ, Miao ZH, Lu P, Wang LF, Xu ZY, et al. Degradation of Mcl-1 through GSK-3beta activation regulates apoptosis induced by bufalin in non-small cell lung cancer H1975 cells. Cell Physiol Biochem. 2017;41(5):2067–76.
Article
CAS
PubMed
Google Scholar
Zhang C, Fu L. Effects of bufalin combined with doxorubicin on the proliferation and apoptosis of human lung cancer cell line A549 in vitro. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017;42(7):762–8.
PubMed
Google Scholar
Huang H, Cao Y, Wei W, Liu W, Lu SY, Chen YB, Wang Y, Yan H, Wu YL. Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells. PLoS ONE. 2013;8(6):e66130.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chang Y, Zhao Y, Zhan H, Wei X, Liu T, Zheng B. Bufalin inhibits the differentiation and proliferation of human osteosarcoma cell line hMG63-derived cancer stem cells. Tumour Biol. 2014;35(2):1075–82.
Article
CAS
PubMed
Google Scholar
Chang Y, Zhao Y, Gu W, Cao Y, Wang S, Pang J, Shi Y. Bufalin inhibits the differentiation and proliferation of cancer stem cells derived from primary osteosarcoma cells through Mir-148a. Cell Physiol Biochem. 2015;36(3):1186–96.
Article
CAS
PubMed
Google Scholar
Lee CH, Shih YL, Lee MH, Au MK, Chen YL, Lu HF, Chung JG. Bufalin induces apoptosis of human osteosarcoma U-2 OS cells through endoplasmic reticulum stress, caspase- and mitochondria-dependent signaling pathways. Molecules. 2017;22(3):437.
Article
PubMed Central
CAS
Google Scholar
Chen H, Zhang L, Zhang L, Du J, Wang H, Wang B. MicroRNA-183 correlates cancer prognosis, regulates cancer proliferation and bufalin sensitivity in epithelial ovarian caner. Am J Transl Res. 2016;8(4):1748–55.
CAS
PubMed
PubMed Central
Google Scholar
Yeh JY, Huang WJ, Kan SF, Wang PS. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate. 2003;54(2):112–24.
Article
CAS
PubMed
Google Scholar
Zhai XF, Fang FF, Liu Q, Meng YB, Guo YY, Chen Z. MiR-181a contributes to bufalin-induced apoptosis in PC-3 prostate cancer cells. BMC Complement Altern Med. 2013;13:325.
Article
PubMed
PubMed Central
CAS
Google Scholar
Fridman E, Lichtstein D, Rosen H. Formation of new high density glycogen-microtubule structures is induced by cardiac steroids. J Biol Chem. 2012;287(9):6518–29.
Article
CAS
PubMed
PubMed Central
Google Scholar